Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Sichuan University
Jinling Hospital, China
Alliance for Clinical Trials in Oncology
Northwestern University
Ruijin Hospital
Shanghai Pulmonary Hospital, Shanghai, China
St. Petersburg State Pavlov Medical University
The First Affiliated Hospital with Nanjing Medical University
National Cancer Institute, Naples
Chongqing University Cancer Hospital
The First Affiliated Hospital with Nanjing Medical University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Zhejiang University
Zhejiang University
Fudan University
Sichuan University
Swedish Medical Center
Swedish Medical Center
Zhongda Hospital
Women's Hospital School Of Medicine Zhejiang University
Zhejiang University
Northwestern University
Sun Yat-sen University
Institute of Hematology & Blood Diseases Hospital, China
The First Affiliated Hospital with Nanjing Medical University
Peking Union Medical College Hospital
PETHEMA Foundation
Beijing Haidian Hospital
Peking Union Medical College Hospital
Czech Lymphoma Study Group
Ruijin Hospital
Guangzhou Institute of Respiratory Disease
Zhengzhou University
British Columbia Cancer Agency
Beijing Tongren Hospital
National Taiwan University Hospital
Fuzhou General Hospital
Sun Yat-sen University
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai Chest Hospital
Peking University Third Hospital
Samsung Medical Center
Samsung Medical Center
Zhejiang Cancer Hospital
Beijing Tongren Hospital
Taizhou Hospital